Recent IPO Schrödinger extends its existing collaboration with AstraZeneca, $AZN, aimed at enhancing the former's Free Energy Perturbation technology for the optimization of key properties of biologics, particularly binding affinity. As technically, it is rising and needs to break the trendlines and hold above $45.